Immunotherapy/Chemo Combinations Show Continued Benefit in NSCLC
Several clinical trials have evaluated the addition of immunotherapy to standard chemotherapy in the frontline treatment of patients with advanced non–small cell lung cancer, all of which echo similar conclusions: these combinations are a mainstay in this population.
Source: OncLive